Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2019Immunological ReviewsOpen Access

STING pathway agonism as a cancer therapeutic

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBlake FloodHarvard UniversityEHEmily F. HiggsUniversity of ChicagoSLShuyin LiShenyang Medical College

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Flood et al. (2019) studied this question.

synapsesocial.com/papers/69fb0ab06d730ca589dd3dc5https://doi.org/10.1111/imr.12765
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers2009 · 3,679 citations
  2. 2Ubiquitination of STING at lysine 224 controls IRF3 activation2017 · 165 citations
  3. 3An Alternative Splicing Isoform of MITA Antagonizes MITA-Mediated Induction of Type I IFNs2014 · 57 citations
  4. 4Activation of STING requires palmitoylation at the Golgi2016 · 735 citations